Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP)
jRCT2031250663Recruiting
- Sponsor
- Sanofi
- Start
- Mar 2026
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Sanofi. Primary endpoint: Safety: adverse events and clinically significant abnormalities. Started Mar 2026; status: recruiting.
02
Drugs
riliprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on jRCT2031250663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250663.